ClinicalTrials.gg
RecruitingNCT03977493Updated Mar 19, 2026

IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia

A Phase 3 interventional study of Xeomin and Placebo - Concentrate in Focal Hand Dystonia, sponsored by Alain Kaelin. Recruiting at 5 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Alain Kaelin · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Feb 2018, registered Apr 2019).
  • Started Feb 2018; still recruiting 8 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a multicenter, double-blind, randomized placebo controlled, parallel group, superiority trial in order to test the superiority of intramuscular injections of IncobotulinumtoxinA against placebo using a 1:1 allocation ratio.

Read the detailed description

After a baseline evaluation, each patient will receive a first injection of IncobotulinumtoxinA or placebo (50:50 randomization) in a double blinding setting. Assessment of the Focal hand dystonia (FHD) will be done at each site by an investigator blinded to the treatment.

A first evaluation of the efficacy will be performed after 6 weeks. After 6 weeks, patients unsatisfied with treatment and wishing to continue the treatment will receive an injection of IncobotulinumtoxinA regardless of the treatment arm they were initially assigned to at baseline. These patients will subsequently be excluded from the study.

A second assessment will be performed after 12 weeks (only for patients not receiving a second injection of IncobotulinumtoxinA at week 6).

02

Conditions studied

  • Focal Hand Dystonia
03

In context

Dystonia, Focal, Task-Specific

26 studies on the registry are indexed under Dystonia, Focal, Task-Specific; 3 are open to participants now.

This study's planned enrollment of 48 is above the median of 15 across 13 interventional studies indexed under Dystonia, Focal, Task-Specific.

Browse Dystonia, Focal, Task-Specific studies →

Lead sponsor

Alain Kaelin is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • as documented by signature
  • Age ≥ 18 years
  • Focal hand dystonia (FHD). Diagnosis must be made by a neurologist specialized in movement disorder (at least 2 years specific training, all partners listed have at least 2 years training)
  • Both idiopathic and secondary FHD are allowed
  • Both drug naive subjects and subjects previously treated with other BoNT-A will be included
  • Patients must be willing and able to comply with the study procedures
  • Female patients of must agree to use an effective method of during the treatment period

Exclusion criteria

Exclusion Criteria:

  • Presence of spasticity, or other central sensorimotor lesion of motor system other than dystonia in the affected limb
  • Peripheral nerve lesion (diagnosis either clinical or electrophysiological) in the affected limb, for example with a muscle weakness at baseline
  • to the class of drugs under study, e.g. known or allergy to BoNT-A toxins including IncobotulinumtoxinA
  • Doses and schedules of any ongoing treatment with potential confounding drugs such as muscle relaxants (for example Tolperison, Tizinadid, Baclofen, Mestinon, Dantrolen), benzodiazepine, neuroleptics or antidepressants have to be kept unchanged throughout the study and no changes should be made between the first trial injection and the end of study visit at week 12.
  • Previous treatment with other BoNT-A less than 3 months before the inclusion in this study
  • Women who are pregnant or breast feeding,
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
  • Participation in another study with drug within the 30 days preceding and during the present study
  • Previous enrolment into the current study
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • Severe depression (>29 as measured with the Beck Depression Inventory, see Appendix 8) or other relevant psychiatric disorder
  • > 2 on the day of injection if the patient is anticoagulated. If INR > 2, the study injection will be delayed until the return to a safer INR.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    Xeomin®

    Intramuscular IncobotulinumtoxinA (Xeomin®) injection under guidance (EMG and/or sonographic monitoring), 2.5 to 40 U in each muscle (max. 5 forearm- and/or hand muscles).

    Drug: Xeomin

  • Placebo comparator
    Placebo concentrate

    Intramuscular Placebo injection under guidance (EMG and/or sonographic monitoring), in each muscle (max. 5 forearm- and/or hand muscles).

    Drug: Placebo - Concentrate

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluation of the efficacy of IncobotulinumtoxinA on focal hand dystonia (FHD)

    To evaluate patient's subjective impairment due to FHD on VAS for handwriting. The VAS for handwriting is a self-assessment scale drawn by the patients on a 10-cm line, on which 0 indicates the worst possible situation and 10 the best possible situation.

    Time frame: 6 weeks

Secondary outcomes

  1. Evaluation of the efficacy of IncobotulinumtoxinA on FHD

    To evaluate patient's subjective impairment due to FHD on VAS for handwriting. The VAS for handwriting is a self-assessment scale drawn by the patients on a 10-cm line, on which 0 indicates the worst possible situation and 10 the best possible situation.

    Time frame: 12 weeks

  2. Evaluation of the effect of IncobotulinumtoxinA on FHD symptoms severity

    To measure change in symptoms severity by using the Symptom Severity Scale (SSS). Total SSS score ranges from 10 (best possible) to 43 (worst possible).

    Time frame: 6 and 12 weeks

  3. Evaluation of the effect of IncobotulinumtoxinA on functional status

    To measure change in functional status by using the Functional Status Scale (FSS). Total FSS score ranges from 0 (best possible) to 40 (worst possible).

    Time frame: 6 and 12 weeks

  4. Evaluation of the effect of IncobotulinumtoxinA on writer's cramp improvement

    To measure the change in writer's cramp measured by the Writer's Cramp Rating Scale (WCRS) - only part A. Total WCRS score ranges from 0 (no improvement) to 28 (marked improvement).

    Time frame: 6 and 12 weeks

  5. Evaluation of the effect of IncobotulinumtoxinA on disease improvement

    To measure the change in the physician's clinical evaluation of the disease by using the CGI-improvement scale. The CGI-improvement scale ranges from 0 to 4 (none, minimal, mild, moderate, excellent).

    Time frame: 6 and 12 weeks

  6. Evaluation of the effect of IncobotulinumtoxinA on writing pressure

    To measure the change in writing pressure by using a pressure sensitive-tablet. Writing Movement pressure will be measured in Pascal.

    Time frame: 6 and 12 weeks

  7. Evaluation of the effect of IncobotulinumtoxinA on writing speed

    To measure the change in writing speed by using a pressure sensitive-tablet. Writing movement speed will be measured in seconds.

    Time frame: 6 and 12 weeks

  8. Evaluation of the effect of IncobotulinumtoxinA on muscle strength

    To measure the change in muscle strength by using the Medical Research Council Scale for Muscle strength. The patient's effort is graded on a scale of 0 (normal muscle) to 5 (no movement).

    Time frame: 6 and 12 weeks

  9. Evaluation of the responders to IncobotulinumtoxinA treatment

    Number of patients showing an improvement of FHD by ≥ 1 points over baseline

    Time frame: 6 and 12 weeks

  10. Evaluation of the overall satisfaction of the patients following IncobotulinumtoxinA treatment

    Patients will answer the following two questions: a) Considering all advantages and disadvantages of this treatment, is the improvement such that you wish to continue this treatment or not? Yes/No b) Do you think that you would need an injection of IncobotulinumtoxinA today? Yes/No

    Time frame: 6 weeks

  11. Need of re-injection

    The physician will judge about whether an injection with IncobotulinumtoxinA is recommended or not (Yes/No)

    Time frame: 6 weeks

  12. Safety outcomes: adverse events

    Incidence and severity of adverse reactions (mild, moderate, severe).

    Time frame: 6 and 12 weeks

  13. Safety outcomes: pain

    Pain assessed by VAS scale. The VAS for pain is a self-assessment scale drawn by the patients on a 10-cm line, on which 0 indicates no pain and 10 an extreme amount of pain.

    Time frame: 6 and 12 weeks

  14. Safety outcomes: weakness

    Weakness assessed by using the CGI-side effect scale and CGI-weakness scale. CGI-side effect scale ranges from 0 to 3 (no, mild, marked, severe side effects). CGI-weakness assessment scale ranges from 0 to 4 (none, \<25%, 26-50%, 51-75%, 76-100% reduction in normal strength).

    Time frame: 6 and 12 weeks

  15. Evaluation of the effect of IncobotulinumtoxinA on depressive symptoms

    To measure the change in depressive symptoms by using the Beck Depression Inventory (BDI). Total BDI score ranges from 0 to 63 with scores \> 29 indicating severe depression and \> 40 extreme depression.

    Time frame: 6 and 12 weeks

07

Study locations

1 of 5 sites recruiting
  • Inselspital - University Hospital Berne
    Bern, 3010, Switzerland
    Not yet recruiting
  • Centre hospitalier universitaire vaudois (CHUV)
    Lausanne, 1001, Switzerland
    Not yet recruiting
  • Neurocentro della Svizzera Italiana
    Lugano, 6900, Switzerland
    Recruiting
  • Neurocenter of St. Gallen
    Sankt Gallen, 9007, Switzerland
    Not yet recruiting
  • USZ- Univerity Hospital Zurich
    Zurich, 8091, Switzerland
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2018 (actual). Primary completion is estimated for Dec 2027, 118 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2019
First posted
Jun 6, 2019
StartActual
Feb 21, 2018
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03977493
Lead sponsor
Alain Kaelin
Collaborators
Clinical Trial Unit Ente Ospedaliero Cantonale
Responsible party
Alain Kaelin (Director of the Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona) — Sponsor-investigator
First posted
Jun 6, 2019
Start date
Feb 21, 2018
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 19, 2026

Study contacts

Alain Kaelin, Prof.
Contact
alain.kaelin@eoc.ch
+41 (0)91 811 62 57

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion